Recommendation of the President – Ibrance (palbociclib)
On 12 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 191/2025 on the reimbursement of the medicinal product Ibrance (palbociclib) under the B.9.FM drug program. “Treatment of patients with breast cancer (ICD-10: C50)”